This year, Omaze, a company that runs prize draws to raise money for charities, has chosen London's Air Ambulance Charity for its latest fundraising campaign.

-Three case studies reinforce clinical trial data demonstrating dramatic healing rates among patients with diabetic foot ulcers treated with OCM™ -CLEVELAND, June 12, 2024 /PRNewswire/ -- Omeza®, a regenerative skincare company that develops marine-based therapies for nonhealing wounds that are hard to treat, presented three case studies showing that diabetic foot ulcers (DFUs) treated weekly with Omeza® OCM™ demonstrated 90 to 100 percent wound closure at 12 weeks. Results of the case studies were presented at the WOCNEXT annual conference, hosted by the Wound, Ostomy, and Continence Nurses Society™ (WOCN®)."Treating diabetic foot ulcers is a persistent challenge because they frequently fail to respond to what are considered topline treatments, and many patients suffer for months or years without relief, severely impacting their quality of life and jeopardizing their health status," said Mary Cheney, CNP, CWS, of Jobst Institute, Toledo, OH."The ongoing results of individual case studies and clinical trials consistently show that Omeza® OCM™ has the ability to move hard-to-heal DFUs from chronic to healing—even wounds of more than a year in duration—within a period of 12 weeks, which is truly encouraging, given the massive toll they take on patients' lives, added Susan Shuman, BS, RN, of Jobst Vascular institute, Toledo, OH.Diabetic foot ulcers are not only painful and burdensome to patients, but they often lead to serious complications such as severe infections, limb amputations, and loss of life. According to the American Diabetes Association, more than 154,000 people with diabetes in the United States undergo amputations each year, and up to 80% of non-traumatic lower limb amputations are due to diabetes complications.1OCM™ is a novel platform comprised of cold-water fish peptides and other pharmaceutical-grade components that harness an individual's innate immune processes to activate healing at the site of the wound. The current data on OCM™ were collected by the Jobst Vascular Institute at ProMedica Health System in Toledo, Ohio, which previously conducted a clinical trial comparing OCM™ to current standards of wound care.Case Study Patient OutcomesPatient one, age 60: At treatment visit 1, his wound of 1-year duration measured 0.37cm. The patient's 12-week percentage area reduction (PAR) was 100%; however, walking caused its reopening, so he reentered the study. His 4-week PAR was 76%, and the wound closed by treatment visit 5.Patient two, age 53: At treatment visit 1, his wound of 12-week duration measured 11.6cm and was reduced to 2.09cm by treatment visit 5